VivoSeq
Oncology

Head and Neck Cancer

21

Pipeline Programs↗

56

Active Trials↗

39

Companies Involved↗

Head and Neck Cancer is an emerging landscape with 21 programs across 39 companies. The most active players are Bristol-Myers Squibb, Sanofi, Sun Pharma. 6 therapies are approved with 1 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

59/100

Pipeline Velocity

48/100

Mech. Concentration

17/100

Completion Rate

69/100

Attrition Rate

22/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Bristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

Phase 1Sanofi logo

Sanofi

1 program

Phase 1Sun Pharma logo

Sun Pharma

1 program

Phase 1I

Imclone

1 program

Phase 1Novartis logo

Novartis

2 programs

Phase 2K

Kenvue Brands

1 program

Approved

Pipeline

Programs by Phase

Analysis

Modality Breakdown

79%

Small molecule

15 of 19 classified programs — the dominant modality here.

21%ALL OTHERSMonoclonal antibody316%Protein / enzyme15%

Small molecule leads; the ring shows all 19 classified programs, each share of the total. Modality classified for 91% of 22 pipeline programs.

Analysis

Trial Status

293

clinical trials

Completed148 · 51%
Terminated45 · 15%
Recruiting30 · 10%
Unknown status23 · 8%
Withdrawn19 · 6%
Active, not recruiting17 · 6%
Other11 · 4%

Clinical Trials

Trial Activity

293 trials

A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer, in Patients With Unknown Primary Head and Neck Cancer (ILLUMINATE STUDY)
Recruiting·UUniversity of Texas Southwestern Medical Center·Phase 2·NCT05576974·120 enrolled
Decitabine in Combination With Standard of Care Therapy for the Treatment of Surgically Resectable HPV-Negative Head and Neck Cancer
Recruiting·MMayo Clinic·Phase 1·NCT06997094·24 enrolled
Response-Adaptive Treatment in Untreated Locoregional HPV-Negative Head and Neck Cancer
Recruiting·UUniversity of Chicago·Phase 2·NCT07065630·38 enrolled
A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)
Recruiting·—·Phase 3·NCT06525220·500 enrolled
Head and Neck Cancer Study Project in the Geriatric Population
Recruiting·—·Phase 3·NCT06998069·20 enrolled
Intensity Modulated Proton or X-Ray Therapy After Surgery for Treatment of Head and Neck Cancer, the HEADLIGHT Study
Recruiting·MMayo Clinic·Phase 2·NCT05075980·174 enrolled
VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer
Recruiting·EEmory University·Phase 1·NCT03690986·50 enrolled
Candida Therapeutic Vaccine in Head and Neck Cancer Patients to Reduce Recurrence
Recruiting·UUniversity of Arkansas·Phase 2·NCT05952934·100 enrolled
Evaluating the Use of Dual Imaging Techniques for Detection of Disease in Patients With Head and Neck Cancer
Recruiting·VVanderbilt-Ingram Cancer Center·Phase 1·NCT05945875·40 enrolled
Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer
Recruiting·VVLP Therapeutics·Phase 1·NCT06736379·41 enrolled
A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer
Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT04722523·40 enrolled
A Study of Decreasing Radiation Therapy and Chemotherapy in People With Head and Neck Cancer
Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT05544136·12 enrolled
Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
Recruiting·National Cancer Institute (NCI)·Phase 2·NCT06980038·44 enrolled
Apixaban or Enoxaparin After Head and Neck Cancer Surgery
Recruiting·—·Phase 4·NCT07189897·76 enrolled
Evaluating 111In Panitumumab for Nodal Staging in Head and Neck Cancer
Recruiting·VVanderbilt-Ingram Cancer Center·Phase 1·NCT05901545·30 enrolled
Page 1 of 20

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)